Want to see GB:THAT full AI Analyst Report?
N4 Pharma (THAT) AI Stock Analysis
Top Page
N4 Pharma
(LSE:THAT)
The score is primarily held down by weak financial performance—persistent losses, very small/volatile revenue, and ongoing cash burn—despite the benefit of having no debt. Technicals add pressure with a clear downtrend (below key moving averages and negative MACD), even though the stock is extremely oversold. Valuation is also constrained by a negative P/E and no provided dividend yield.
N4 Pharma (THAT) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 4.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 737.27K
- Price to Earnings (P/E)
- -7.2
- Beta (1Y)
- 1.26
- Revenue Growth
- 2.12%
- EPS Growth
- 29.17%
- Country
- UK
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
N4 Pharma Business Overview & Revenue Model
Company Description
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular...
How the Company Makes Money
N4 Pharma is an R&D-stage drug delivery company; specific, consistently recurring commercial revenue streams are not publicly evidenced in the information available to me here, so a definitive breakdown of how it currently makes money cannot be state...
N4 Pharma Financial Statement Overview
Summary
Financials reflect an early-stage biotech profile with high execution/financing risk: revenue is very small and volatile, while EBIT and net income are deeply negative with extremely weak net margins. Cash flow is also consistently negative (ongoing cash burn), though outflows narrowed versus 2023. The main offset is a debt-free balance sheet, which reduces near-term solvency risk despite continued losses.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7,216 | 7,264 | 7,282 | 1,953 | 0 | 0 |
| Gross Profit | 0 | 7,264 | 7,282 | 1,953 | 0 | 0 |
| EBITDA | -1.39M | -1.10M | -1.22M | -1.33M | -1.19M | -1.84M |
| Net Income | -1.46M | -1.21M | -1.06M | -1.27M | -1.03M | -1.54M |
Balance Sheet | ||||||
| Total Assets | 2.71M | 1.17M | 775.77K | 1.28M | 2.17M | 2.34M |
| Cash, Cash Equivalents and Short-Term Investments | 1.50M | 1.08M | 625.97K | 1.03M | 1.92M | 1.78M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 245.66K | 97.96K | 124.37K | 81.73K | 77.89K | 212.73K |
| Stockholders Equity | 2.46M | 1.07M | 647.65K | 1.13M | 2.09M | 2.13M |
Cash Flow | ||||||
| Free Cash Flow | -1.46M | -1.16M | -971.50K | -1.21M | -828.26K | -1.77M |
| Operating Cash Flow | -1.46M | -1.16M | -971.50K | -1.21M | -828.26K | -1.77M |
| Investing Cash Flow | 0 | 0 | 0 | 781 | 0 | 0 |
| Financing Cash Flow | 1.24M | 1.61M | 570.36K | 315.90K | 963.77K | 677 |
N4 Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:THAT, the sentiment is Negative. The current price of 0.57 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 0.60, and below the 200-day MA of 0.58, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 23.47 is Positive, neither overbought nor oversold. The STOCH value of 35.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:THAT.
N4 Pharma Peers Comparison
Overall Rating
GB:EAH59Neutral
GB:PXS56Neutral- GB:THAT43Neutral
GB:STX42Neutral
GB:CHLL38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:EAH | 59Neutral | GBP 64.71M | 29.57 | 2.55% | ― | 9.96% | 29.72% |
| GB:PXS | 56Neutral | GBP 18.77M | -80.00 | -44.68% | ― | -2.14% | 0.00% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:THAT | 43Neutral | GBP 14.18M | -7.19 | -82.76% | ― | 2.12% | 29.17% |
| GB:STX | 42Neutral | GBP 60.69M | -7.72 | 64.57% | ― | 36.19% | 60.75% |
| GB:CHLL | 38Underperform | GBP 888.98K | -0.00 | 233.76% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:THAT | N4 Pharma | 0.57 | -0.03 | -4.17% | |
| GB:EAH | Eco Animal Health | 95.50 | 12.50 | 15.06% | |
| GB:CHLL | Chill Brands Group PLC | 1.70 | -8.80 | -83.81% | |
| GB:HELD | Mountfield Group plc | 0.90 | -0.05 | -5.26% | |
| GB:PXS | Provexis plc | 0.80 | 0.22 | 37.93% | |
| GB:STX | Shield Therapeutics | 5.65 | -1.40 | -19.86% |
N4 Pharma Corporate Events
Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline
PositiveThalia Therapeutics reported interim results marking its strategic transformation from a delivery-platform business into a diversified, clinical-stage RNA therapeutics company in oncology and cardiovascular disease. The appointment of CEO Dr David So...
Thalia Therapeutics Secures Chinese Patent for Lead AML Drug miRisten
PositiveThalia Therapeutics has secured a new patent in China for its lead acute myeloid leukaemia drug candidate miRisten, extending protection for the RNA-based therapy in a major oncology market. The patent builds on existing rights licensed from City of...
Thalia Therapeutics Advances Dual-Target RNA Cardiovascular Drug THAT-002
PositiveThalia Therapeutics has completed initial chemistry synthesis for THAT-002, a bispecific siRNA gene-silencing therapy targeting PCSK9 and lipoprotein(a) to lower cardiovascular disease risk. The programme, developed with WuXi AppTec, marks a key earl...
Thalia Therapeutics Advances RNA Portfolio After Strategic Transformation
PositiveThalia Therapeutics has completed its transition into a clinical-stage RNA therapeutics business after rebranding from N4 Pharma and acquiring Sanmirna Therapeutics, and will report interim results for the six months to 30 June 2026 on 30 September....
Thalia Therapeutics Updates Voting Rights as RNA Therapy Pipeline Advances
PositiveThalia Therapeutics plc, an AIM-listed clinical-stage biotech specialising in RNA-based therapies for cancer and cardiovascular conditions, is advancing a differentiated pipeline anchored by validated genetic targets and proprietary delivery technolo...
Thalia Therapeutics Grants Major Director Option Package Tied to Share Price Targets
NeutralThalia Therapeutics has granted options over 200,000,000 ordinary shares to five directors under its share option plan, following its recent AGM and the completion of the acquisition of Sanmirna Therapeutics. The board says the ten-year options, pric...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 08, 2026